Lead Product(s): Buprenorphine
Therapeutic Area: Psychiatry/Psychology Product Name: Sixmo
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Molteni Farmaceutici
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 14, 2020
Under the terms of the agreement, Accord will commercialize Sixmo®▼ (buprenorphine implant), an opioid agonist therapy treatment, delivered through a first-of-its-kind implant, placed under the skin for six-months.